tbuckley/cabot-search huggingface dataset:
Phase IB study of FOLFIRINOX plus PF-04136309 in patients with borderline resectable and locally advanced pancreatic adenocarcinoma (PC).
Authors: Andrea Wang-Gillam, Timothy M. Nywening, Dominic E. Sanford, Albert C. Lockhart, Rama Suresh, Benjamin R. Tan, Kian-Huat Lim, Steven Sorscher, Kathryn Fowler, Manik A. Amin, Anna Roshal, Douglas Adkins, Rebecca Nieman, Roheena Z. Panni, David G DeNardo, Peter S. Goedegebuure, William G. Hawkins, Ryan C. Fields, Steven M. Strasberg, David Linehan
Journal: Journal of Clinical Oncology (2015)

338 Background: PF-04136309 (a novel CCR2 inhibitor) has shown anti-tumor activity in the preclinical setting in PC by depleting inflammatory monocytes and tumor associated macrophages (TAM) that contribute to an immunosuppressive tumor microenvironment. We hypothesized that combining PF-04136309 with FOLFIRINOX may improve clinical outcomes in PC. Methods: This is a phase Ib study with a dose de-escalation schema given the minimal toxicity of PF-04136309. The study includes Arm A (FOLFIRINOX only), Arm B (FOLFIRINOX plus PF-04136309) and an expansion cohort at the rapid phase II dose (RP2D). FOLFIRINOX (oxaliplatin 85 mg/m 2 , irinotecan 180 mg/m 2 , LV 400 mg/m 2 , 5FU bolus 400 mg/m 2 and 2,400 mg/m 2 over 46 hours) was administered every two weeks. PF-04136309 at 500 mg twice daily via oral route was the starting dose level for Arm B. Treatment response was assessed after 6 cycles of treatment. Bone marrow biopsy and EUS/FNA at baseline and post 2 cycles were performed to assess the impact of treatment on the prevalence and function of inflammatory monocytes in the blood, bone marrow and tumor. Results: A total of 41 patients have been enrolled in the study to date (6 in Arm A, 8 in Arm B and 27 in the expansion cohort). The mean age of patients was 61.1 (range 45-75 yrs), male/female: 21/20, Caucasian/others: 32/9, borderline/locally advanced: 7/34. PF-04136309 at the starting dose did not result in additional toxicities when combined with FOLFIRINOX and it is the RP2D. Out of 35 patients treated with FOLFIRINOX plus PF-04136309, 6 are still in treatment, 6 are non-evaluable (withdrew consent or had poor tolerance). Of the 23 evaluable patients, 21 (91.3%) completed all 6 cycles; 12 (52.2%) had PR by RECIST and 11 (47.8%) had SD. Curative resections were achieved in 4 out of 5 with borderline resectable and 2 with locally advanced PC. Moreover, blockade of TAM mobilization was demonstrated by FACS and qPCR analysis of baseline and post-treatment FNA biopsies. Conclusions: Combing PF-04136309 with FOLFIRINOX is safe and tolerable. The regimen resulted in impressive treatment response and it further validated CCR2 inhibition in PC. Survival data and more correlative science will be forthcoming. Clinical trial information: 01413022.
Phenytoin silver: a new nanocompound for promoting dermal wound healing via comprehensive pharmacological action
Authors: Xiao-yu Ai, Hui-juan Liu, Cheng Lu, Cai-li Liang, Yan Sun, Shuang Chen, Bo Sun, Yang Li, Yan-rong Liu, Qiang Zhang, Xue-qiang Liu, Ting Xiao, Xue-shuang Jing, Tao Sun, Hong-gang Zhou, Cheng Yang
Journal: Theranostics (2017)

Phenytoin, an antiepileptic drug, has been widely used for wound healing. Inspired by previous studies, phenytoin silver (PnAg), a sparingly soluble silver nanocompound, was synthesized which exhibited good therapeutic efficacy in tissue repair with low toxicity (LD50 >5 g/kg). In vivo studies showed that PnAg could accelerate dermal wound healing and strong inflammation control in Sprague-Dawley rats (SD rat) and Bama minipigs. Due to its low solubility, PnAg led to low toxicity and blood enrichment in animals. Furthermore, PnAg could upregulate the promoter activity of Jak, Stat3, and Stat3 downstream proteins. Therefore, PnAg may serve as an effective therapeutic compound for wound healing through regulating the gp130/Jak/Stat3 signaling pathway.
Inhibition of anti‐IgE induced skin responsein normals by formoterol, a new β<sub>2</sub>‐adrenoceptor agonist, and terbutaline
Authors: R. Gronneberg, O. Zetterström
Journal: Allergy (1990)

Formoterol, a new β 2 selective long‐acting bronchodilator, was compared with terbutaline in terms of ability to inhibit dual phase skin reactions to anti‐human IgE in volunteers. Anti‐IgE induced an early wheal and flare reaction (WFR) followed by a progressively increasing induration, the late phase reaction (LCR), lasting 24 h. Intradermal injection of formoterol 20 ng or terbutaline 500 ng 5 min before challenge gave equal inhibition of the WFR. The subsequent LCR was suppressed by formoterol (30 %) for the whole 24 h period, while terbutaline only attenuated the first 4 h period. Increasing the dose range of both drugs 25‐fold, caused a further analogous reduction of the WFR to anti‐IgE. In this higher dose range formoterol (0.5 ng) antagonized the following 1–24 h LCR by 50 %, while terbutaline (25 μg) only attenuated the LCR by an average of 20 %, with higher effect in the first 6 h period. The anti‐LCR capacity of formoterol was highly superior to that of terbutaline ( P &lt; 0.001). The histamine‐elicited wheal response was attenuated by both drugs, but they had no effect on the flare response, favouring an anti‐permeability action of both compounds. The data support the concept that terbutaline, given locally in a single dose shortly before challenge, inhibits the mast cell mediator release reaction with limited consequences for the following LCR. In contrast to terbutaline, formoterol exerted a substantial anti‐LCR action, probably by interfering with inflammatory mechanisms after the initial mast cell mediator release.
How often is adjuvant FOLFOX (Adj FOLFOX) discontinued for toxicity among colon cancer patients in the routine care setting?
Authors: D. Romanus, M. Weiser, A. TerVeer, J. Skibber, J. Wilson, A. Rajput, Y. Wong, A. Benson, J. Niland, D. Schrag
Journal: Journal of Clinical Oncology (2009)

9530 Background: Although 12 cycles of Adj FOLFOX are recommended for stage III and high risk stage II colon cancer, toxicity may preclude completion of treatment. We used the NCCN Colorectal Cancer Outcomes Database to identify how frequently Adj FOLFOX is discontinued prematurely for toxicity in a non-clinical trial population. Methods: Newly diagnosed stage II-III colon cancer pts treated with Adj FOLFOX at 7 NCI-designated comprehensive cancer centers between 9/05–12/07 were identified. We assessed completion of the prescribed adjuvant chemotherapy (AC) course, including Adj FOLFOX and 5FU-based adjuvant treatment alone subsequent to discontinuation of oxaliplatin (oxal). Dose limiting toxicity (DLT) of Adj FOLFOX was defined as premature discontinuation of Adj FOLFOX due to toxicity. We evaluated potential predictors of Adj FOLFOX DLT, including older age and history of diabetes in a multivariable logistic model controlling for stage and center. We measured the duration of Adj FOLFOX use in weeks, from first to last dose. Results: 293 pts began Adj FOLFOX. Pts who experienced DLT (40%) had a shorter duration of Adj FOLFOX and were less likely to complete AC, even after oxal was discontinued. The only significant predictor of experiencing a DLT was a history of diabetes. Conclusions: Our analysis of patients treated outside of a clinical trial demonstrated a notably high rate of discontinuation of Adj FOLFOX due to DLT, particularly in pts with diabetes. The results underscore the need for systematic assessment of toxicity especially among diabetics. [Table: see text] [Table: see text]
The release and trans-synaptic transmission of Tau via exosomes
Authors: Yipeng Wang, Varun Balaji, Senthilvelrajan Kaniyappan, Lars Krüger, Stephan Irsen, Katharina Tepper, RamReddy Chandupatla, Walter Maetzler, Anja Schneider, Eckhard Mandelkow, Eva-Maria Mandelkow
Journal: Molecular Neurodegeneration (2017)

Tau pathology in AD spreads in a hierarchical pattern, whereby it first appears in the entorhinal cortex, then spreads to the hippocampus and later to the surrounding areas. Based on this sequential appearance, AD can be classified into six stages ("Braak stages"). The mechanisms and agents underlying the progression of Tau pathology are a matter of debate. Emerging evidence indicates that the propagation of Tau pathology may be due to the transmission of Tau protein, but the underlying pathways and Tau species are not well understood. In this study we investigated the question of Tau spreading via small extracellular vesicles called exosomes.Exosomes from different sources were analyzed by biochemical methods and electron microscopy (EM) and cryo-EM. Microfluidic devices that allow the culture of cell populations in different compartments were used to investigate the spreading of Tau.We show that Tau protein is released by cultured primary neurons or by N2a cells overexpressing different Tau constructs via exosomes. Neuron-derived exosomal Tau is hypo-phosphorylated, compared with cytosolic Tau. Depolarization of neurons promotes release of Tau-containing exosomes, highlighting the importance of neuronal activity. Using microfluidic devices we show that exosomes mediate trans-neuronal transfer of Tau depending on synaptic connectivity. Tau spreading is achieved by direct transmission of exosomes between neurons. In organotypic hippocampal slices, Tau-containing exosomes in conditioned medium are taken up by neurons and microglia, not astrocytes. In N2a cells, Tau assemblies are released via exosomes. They can induce inclusions of other Tau molecules in N2a cells expressing mutant human Tau. We also studied exosomes from cerebrospinal fluid in AD and control subjects containing monomeric and oligomeric Tau. Split-luciferase complementation reveals that exosomes from CSF can promote Tau aggregation in cultured cells.Our study demonstrates that exosomes contribute to trans-synaptic Tau transmission, and thus offer new approches to control the spreading of pathology in AD and other tauopathies.
A story in a tea cup
Authors: Radhika Natarajan
Journal: BMJ (2017)

I was at a statewide medical conference. The organisers had provided an all-day counter offering fresh tea, alongside the standard “tea bag” facilities.

No one can resist freshly brewed tea, so I walked out of a sonorous session for a hot cuppa to clear my brain. The surging crowd of medicos outside the free tea stall put the seminar halls to …
Treatment-Related MDS/AML after Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL): An EBMT Survey.
Authors: Peter Dreger, Anja van Biezen, Kees Brukx, Marc Boogaerts, Mauricette Michallet, Donald Milligan, Dietger W. Niederwieser
Journal: Blood (2005)
Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligo
Authors: Maiana Larsabal, Aurélie Marti, Clément Jacquemin, Jérôme Rambert, Denis Thiolat, Léa Dousset, Alain Taieb, Caroline Dutriaux, Sorilla Prey, Katia Boniface, Julien Seneschal
Journal: Journal of the American Academy of Dermatology (2017)
Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia
Authors: S Peirs, V Frismantas, F Matthijssens, W Van Loocke, T Pieters, N Vandamme, B Lintermans, M P Dobay, G Berx, B Poppe, S Goossens, B C Bornhauser, J-P Bourquin, P Van Vlierberghe
Journal: Leukemia (2017)
Comparison of the Fresenius COM.TEC with the COBE Spectra for the Collection and Processing of Peripheral Blood Progenitor Cells for Autologous Transplantation
Authors: Cheryl J Hutchins, Glen A Kennedy, Kari L Mudie, Emilia C Barnes, Nicola Lumley, Beth Hickey, Travis J Mitchell, Trineane Patch, Phillippa C Smith, Simon Durrant
Journal: Blood (2008)
Detection of Significantly Increased Frequencies of Proteinase-3 (Myeloblastin) - Specific CD8+ T-Cells in Patients with De Novo Diagnosed Hepatitis C and Infiltration of Liver Tissue with Proteinase 3 Overexpressing Mononuclear Cells.
Authors: Andreas Burchert, Thomas Berg, Markus Ritter, Peter Barth, Andreas Neubauer
Journal: Blood (2004)
Vascular Geometry and Flow Profile Mediate Pathological Cell-Cell Interactions in Sickle Cell Disease As Measured with "Do-It-Yourself" "Endothelial-Ized" Microfluidics
Authors: Robert Mannino, David R Myers, Byungwook Ahn, Hope Gole, Yichen Wang, Angela Lin, Robert Guldberg, Don Giddens, Lucas Timmins, Wilbur A Lam
Journal: Blood (2014)
Epidemiology of Fungal Infections in Hematological Malignancies in Italy: SEIFEM-2004 Study (Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne).
Authors: Livio Pagano, Morena Caira, Anna Candoni, Massimo Offidani, Bruno Martino, Vincenzo Liso, Marco Picardi, Alessandro Bonini, Anna Chierichini, Rossella Fanci, Cecilia Caramatti, Rosangela Invernizzi, Andrea Gallamini, Maria Enza Mitra, Lorella Melillo, Bernardino Allione, Luana Fianchi, Paolo Falcucci, Caterina Giovanna Valentini, Maria Teresa Van Lint, Corrado Girmenia, Anna Maria Nosari
Journal: Blood (2005)
TRAIL Receptor 1 and TRAIL Receptor 2 Monoclonal Antibodies Induce Apoptosis and Increase Susceptibility to Cytostatic Agents in Mantle Cell Lymphoma.
Authors: Malte Rieken, Alessandro Pastore, Oliver Weigert, Marc Weinkauf, Grit Hutter, Yvonne Zimmermann, Wolfgang Hiddemann, Martin Dreyling
Journal: Blood (2006)
Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.
Authors: Shaji Kumar, Martha Q. Lacy, Angela Dispenzieri, Francis Buadi, Suzanne R. Hayman, David Dingli, Francesca Gay, William Hogan, S. Vincent Rajkumar, Morie A Gertz
Journal: Blood (2009)
Highly Restricted Usage of Immunoglobulin Light Chain IGKV3-20 with Stereotyped Sequence in Primary Cold-Agglutinin Disease (CAD)
Authors: Agnieszka Malecka, Gunhild Trøen, Anne Tierens, Ingunn Østlie, Ulla Randen, Sigbjorn Berentsen, Geir Tjønnfjord, Jan M.A. Delabie
Journal: Blood (2015)
Randomized controlled trial comparing Billroth-I and Roux-en-Y reconstruction in distal gastrectomy for gastric cancer.
Authors: J. Fujita, H. Imamura, S. Takiguchi, K. Fujitani, I. Miyashiro, K. Kobayashi, Y. Kimura, C. Ebisui, J. Matsuyama, Y. Doki
Journal: Journal of Clinical Oncology (2011)

65 Background: In distal subtotal gastrectomy for gastric cancer, Billroth-I (B-I) reconstruction has been performed predominantly in Japan, while increasing number of surgeons chose Roux-en-Y (R-Y) reconstruction recently. To evaluate the safety and superiority of R-Y we conducted a multi-institutional prospective randomized controlled trial. Methods: Gastric cancer patients who underwent distal gastrectomy were randomized to B-I or R-Y intraoperatively. The primary endpoint was the ratio of body weight loss 1 year after surgery, the secondary endpoints were the incidence of delayed gastric emptying (DGE) and postoperative morbidity. Results: Between Aug 2005 and Dec 2008, a total of 332 patients were enrolled and 163 patients were assigned to B-I and 169 patients to R- Y. The patient's characteristics were well balanced between the two groups. The operation time was significantly longer in R-Y than B-I (median 180 min in B-I vs 214 min in R-Y, p &lt; 0.0001). The postoperative morbidity was 14 patients (8.6%) in B-I and 23 (13.6%) in R-Y (p = 0.14), the incidence of DGE was 7 (4.3%) in B-I vs 16 (9.5%) in R-Y (p = 0.06), and the hospital stay after surgery was 14.1days in B-I vs 16.4 days in R-Y (p = 0.02). There was no hospital death in the two groups. The body weight loss at 1 year after surgery compared to preoperation was -5.4kg (-9.1%) in B-I vs -6.2kg (-9.8%) in R-Y (p = 0.11). Conclusions: The advantage of R- Y reconstruction compared to B-I was not proved in terms of postoperative morbidity either the body weight loss 1 year after surgery. No significant financial relationships to disclose.
Breast screening benefits have been overstated, Danish study finds
Authors: Jacqui Wise
Journal: BMJ (2017)

Seventeen years of organised breast screening in Denmark has not reduced the incidence of advanced tumours but has markedly increased the incidence of non-advanced tumours and ductal carcinoma in situ, research published in the Annals of Internal Medicine has shown.1

The researchers calculated that one in three breast tumours detected in women aged 50 to 69 was probably overdiagnosed and said that screening mammography did not seem to have delivered its promised benefit of earlier diagnosis.

Organised breast cancer screening programmes began in various regions of …
Identification of a First in Class GSK3-Alpha Selective Inhibitor As a New Differentiation Therapy for AML
Authors: Lina Benajiba, Florence Wagner, Linda Ross, Ilene Galinsky, Daniel J. DeAngelo, Jennifer Gale, Jen Pan, Yan-Lin Zhang, Joshua Sacher, Michel Weiwer, Richard M. Stone, Edward Holson, Kimberly Stegmaier
Journal: Blood (2015)
Preclinical Evaluation of CRx-501, a Potent Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma
Authors: Richard J Rickles, Laura Pierce, Thomas Giordano, William Avery, Melissa Farwell, David Crowe, Winnie F. Tam, Mei Chen, Vikram Kansra, Douglas W. McMillin, Kenneth C Anderson, Constantine Mitsiades, Margaret S. Lee
Journal: Blood (2008)
A Retrospective Epidemiological Analysis of 1572 Cases of Ph1- Myeloprolypherative Neoplasms (MPNs) From 9 Centers In the Latium: Preliminary Results
Authors: Marco Montanaro, Roberto Latagliata, Enrico Montefusco, Michele Cedrone, Nicoletta Villivà, Ettore Cotroneo, Angela Rago, Francesca Spirito, Marianna De Muro, Massimo Breccia, Barbara Anaclerico, Raffaele Porrini, Gloria Pessina, Stefano Felici, Giulio Trapè, Agostino Tafuri, Maria Gabriella Mazzucconi, Giuseppe Cimino, Ignazio Majolino, Giuseppe Avvisati, Francesco Lo Coco, Alessandro Andriani
Journal: Blood (2010)
Statin Eligibility Under American and European Cholesterol Guidelines—Reply
Authors: Jerry C. Lee, Tomasz Zdrojewski, Ann Marie Navar
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions
Authors: Marc Damelin, Alexander Bankovich, Jeffrey Bernstein, Justin Lucas, Liang Chen, Samuel Williams, Albert Park, Jorge Aguilar, Elana Ernstoff, Manoj Charati, Russell Dushin, Monette Aujay, Christina Lee, Hanna Ramoth, Milly Milton, Johannes Hampl, Sasha Lazetic, Virginia Pulito, Edward Rosfjord, Yongliang Sun, Lindsay King, Frank Barletta, Alison Betts, Magali Guffroy, Hadi Falahatpisheh, Christopher J. O’Donnell, Robert Stull, Marybeth Pysz, Paul Escarpe, David Liu, Orit Foord, Hans Peter Gerber, Puja Sapra, Scott J. Dylla
Journal: Science Translational Medicine (2017)

PTK7 is a tumor-initiating cell antigen, which can be targeted with an antibody-drug conjugate to confer sustained tumor regressions.
Debunking early single sport specialisation and reshaping the youth sport experience: an NBA perspective
Authors: John P DiFiori, Joel S Brenner, Dawn Comstock, Jean Côté, Arne Güllich, Brian Hainline, Robert Malina
Journal: British Journal of Sports Medicine (2017)

Among many parents and coaches, it is believed that early single sport specialisation is essential for future competitive sport success and, further, that a high level of achievement in youth sports predicts future success. Owing to these misconceptions, youth sport has become focused on results at young ages rather than the overall development process, including physical and psychosocial health and well-being.

The emphasis on competitive success in youth sports has been driven by a variety of factors including efforts to make elite travel or club teams, attend exclusive camps or showcase events, secure high school roster spots, garner collegiate scholarships and achieve professional careers. In addition, in the USA, the college recruiting process itself is a significant issue, with those as young as the eighth grade committing to a college programme.1 All of this has led to pressure to begin high-intensity training and single sport specialisation in childhood. As a consequence, many parents and young athletes are concerned that not specialising early will place them at a disadvantage in achieving their sport-related goals. In the sport of basketball, a recent National Collegiate Athletic Association (NCAA) survey found that ∼49% of men and 55% of women at the Division 1 level …
Genome Wide SNP Array (SNPa) Analysis Reveals Clonal Evolution During Clinical Course in Waldenstrom's Macroglobulinemia (WM)
Authors: Stephanie Poulain, Christophe Roumier, Charles Herbaux, Aline Renneville, Elisabeth Bertrand, Agnes Daudignon, Sabine Tricot, Valérie Soenen, Catherine Roche-Lestienne, Olivier Nibourel, Bruno Quesnel, Claude Preudhomme, Patrick Duthilleul, Xavier Leleu
Journal: Blood (2012)
Inhibition of Phosphodiesterase 9A (PDE9A) Significantly Reduces Cytokine-Stimulated Adhesion of Neutrophils From Sickle Cell Disease Individuals, in Vitro, but Not Red Cell Adhesion.
Authors: Lediana I Miguel, Camila B. Almeida, Carla F Franco-Penteado, Marcos André C Bezerra, Fabiola Traina, Venina M Dominical, Aderson S Araujo, Sara T.O. Saad, Fernando F. Costa, Nicola Conran
Journal: Blood (2009)
Vaccination with MAGE-3 Protein Can Induce a Potent Immune Response in a Healthy Donor Which Can Be Adoptively Transferred Via Stem Cell Transplant (Tx) to a Multiple Myeloma (MM) Patient.
Authors: Sacha Gnjatic, Susann Szmania, Amberly Moreno, M. Cottler-Fox, John Shaughnessy, Bart Barlogie, Lloyd Old, Guido Tricot, Frits van Rhee
Journal: Blood (2005)
Genotype-Phenotype Correlations in Hereditary Elliptocytosis (HE) and Hereditary Pyropoikilocytosis (HPP)
Authors: Omar Niss, Satheesh Chonat, Karol Kerr, Patrick T. McGann, Marya Obaid Almansoori, Maa-Ohui Quarmyne, Kejian Zhang, Theodosia A. Kalfa
Journal: Blood (2015)
Plasmablastic Lymphoma Among HIV-Positive Patients: A Curable Entity? Results of a Single Centre's Experience
Authors: Chiara Cattaneo, Alessandro Re, Annalisa Peli, Salvatore Casari, Stefano Fogazzi, Francesca Antoniazzi, Chiara Pagani, Francesca Schieppati, Alfredo Scalzini, Francesco Castelli, Giuseppe Rossi
Journal: Blood (2012)
Mesenchimal Stroma Cells From Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia Show Distinct Cytogenetic and DNA-Mutation Data as Compared with Bone Marrow Leukemic Blasts.
Authors: Olga Blau, Wolf-Karsten Hofmann, Claudia D Baldus, Gundula Thiel, Florian Nolte, Elke Schuemann, Ouidad Benlasfer, Annette Sindram, Eckhard Thiel, Igor W. Blau
Journal: Blood (2009)
Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)
Authors: Ravi Vij, Betty Y. Chang, Jesus G. Berdeja, Carol Ann Huff, Nikoletta Lendvai, Yu-Tzu Tai, Stella Chang, Davina Moussa, Joseph J. Buggy, Laurence Elias, Paul G. Richardson
Journal: Blood (2012)